uracil has been researched along with Hepatitis C in 61 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults." | 9.34 | Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. ( Alston-Smith, BL; Cohen, DE; Cramer, YS; Morse, GD; Rosenkranz, SL; Schmidt, J; Sulkowski, M; Venuto, CS; Wyles, DL, 2020) |
| "Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients." | 9.24 | TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. ( Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D, 2017) |
| "In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1." | 8.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| "The combination of pegylated-interferon and ribavirin (PegIFN+RBV) is currently the gold standard in treating chronic hepatitis C virus (HCV) patients in Malaysia and is reimbursed by the Malaysian authorities." | 7.96 | Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. ( Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S, 2020) |
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 7.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| "The warfarin management strategy for a mechanical mitral valve patient initiated on a ritonavir-based hepatitis C treatment regimen is described." | 7.91 | Inductive Effect of a Ritonavir-Containing Hepatitis C Treatment Regimen on Warfarin in a Patient-A Case Report. ( Gaspar, JL; Rosene, AC, 2019) |
| "Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD ± RBV), was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015." | 7.88 | Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. ( Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C, 2018) |
| "The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection." | 7.85 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. ( Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 7.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 7.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 7.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| " The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study." | 6.82 | Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ( Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 6.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| "The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily." | 5.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| " Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were collected locally." | 5.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 5.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| "AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults." | 5.34 | Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. ( Alston-Smith, BL; Cohen, DE; Cramer, YS; Morse, GD; Rosenkranz, SL; Schmidt, J; Sulkowski, M; Venuto, CS; Wyles, DL, 2020) |
| "Some individuals with hepatitis C virus infection treated with direct-acting antivirals require ribavirin to maximize sustained virological response rates." | 5.27 | Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. ( Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z, 2018) |
| "Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients." | 5.24 | TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. ( Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D, 2017) |
| "ABT-450, ombitasvir, and dasabuvir are direct-acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus (HCV) infection." | 5.20 | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ( Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T, 2015) |
| "The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide." | 5.19 | ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. ( Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O, 2014) |
| "AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection." | 4.95 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse. ( King, JR; Menon, RM, 2017) |
| "Age, APACHE score at ICU admission, neurological disease, sepsis and duration of mechanical ventilation were all independent risk factors for the development of delirium in ICU patients." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "In this retrospective study, we evaluated the efficacy and safety of the combination of ombitasvir + paritaprevir/ritonavir and dasabuvir in 10 adult patients with hemophilia A, 4 patients with hemophilia B, and 1 patient with von Willebrand disease who were infected with hepatitis C genotype 1." | 4.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| "Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according to updated Summary of Product Characteristics." | 3.96 | Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. ( Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D, 2020) |
| "The combination of pegylated-interferon and ribavirin (PegIFN+RBV) is currently the gold standard in treating chronic hepatitis C virus (HCV) patients in Malaysia and is reimbursed by the Malaysian authorities." | 3.96 | Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. ( Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S, 2020) |
| "The warfarin management strategy for a mechanical mitral valve patient initiated on a ritonavir-based hepatitis C treatment regimen is described." | 3.91 | Inductive Effect of a Ritonavir-Containing Hepatitis C Treatment Regimen on Warfarin in a Patient-A Case Report. ( Gaspar, JL; Rosene, AC, 2019) |
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 3.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| "Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD ± RBV), was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015." | 3.88 | Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. ( Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C, 2018) |
| "The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection." | 3.85 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. ( Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017) |
| "The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients." | 3.83 | Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. ( Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A, 2016) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 3.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 3.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| "A 40-year-old man, diagnosed with decompensated liver cirrhosis because of hepatitis C virus, was on the wait list for a liver transplant when he began treatment with the direct-acting antivirals simeprevir 150 mg and sofosbuvir 400 mg." | 3.83 | First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List. ( Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K, 2016) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 3.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 2.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| " The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study." | 2.82 | Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ( Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016) |
| "The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily." | 1.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| " Direct-acting antiviral therapy is efficacious and safe even in patients with advanced liver disease and/ or previous virological failure; Model-for-End-Liver-Disease <10 and alanine aminotransferase reduction during therapy were found to be reliable predicting markers of sustained-virological-response." | 1.51 | Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. ( Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| "At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015." | 1.46 | Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. ( Rostkowska, K; Simon, K; Szymanek-Pasternak, A, 2017) |
| " Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D." | 1.46 | Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. ( Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017) |
| " Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were collected locally." | 1.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 1.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 50 (81.97) | 24.3611 |
| 2020's | 10 (16.39) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YY | 1 |
| Huang, YH | 1 |
| Wu, TH | 1 |
| Loong, CC | 1 |
| Hsu, CC | 1 |
| Chou, YC | 1 |
| Chang, YL | 1 |
| Öksüz, Z | 1 |
| Üçbilek, E | 1 |
| Serin, MS | 1 |
| Yaraş, S | 1 |
| Temel, GÖ | 1 |
| Sezgin, O | 1 |
| Sonsuz, A | 1 |
| Bozcan, S | 1 |
| Hatemi, İ | 1 |
| Özdemir, S | 1 |
| Canbakan, B | 1 |
| Yıldırım, S | 1 |
| Gültürk, İ | 1 |
| Ar, C | 1 |
| Danış, N | 1 |
| Toz, H | 1 |
| Ünal, N | 1 |
| Yılmaz, M | 1 |
| Turan, İ | 1 |
| Günşar, F | 1 |
| Karasu, Z | 1 |
| Ersöz, G | 1 |
| Özkahya, M | 1 |
| Akarca, US | 1 |
| De Pace, V | 1 |
| Morelli, MC | 1 |
| Ravaioli, M | 1 |
| Maggi, F | 1 |
| Galli, S | 1 |
| Vero, V | 1 |
| Re, MC | 1 |
| Cescon, M | 1 |
| Pistello, M | 1 |
| Venuto, CS | 1 |
| Cramer, YS | 1 |
| Rosenkranz, SL | 1 |
| Sulkowski, M | 1 |
| Wyles, DL | 1 |
| Cohen, DE | 4 |
| Schmidt, J | 1 |
| Alston-Smith, BL | 1 |
| Morse, GD | 1 |
| Zarębska-Michaluk, D | 1 |
| Piekarska, A | 1 |
| Jaroszewicz, J | 1 |
| Klapaczyński, J | 1 |
| Mazur, W | 1 |
| Krygier, R | 1 |
| Belica-Wdowik, T | 1 |
| Baka-Ćwierz, B | 1 |
| Janczewska, E | 1 |
| Pabjan, P | 1 |
| Dobracka, B | 1 |
| Lorenc, B | 1 |
| Tudrujek-Zdunek, M | 1 |
| Tomasiewicz, K | 1 |
| Sitko, M | 1 |
| Garlicki, A | 1 |
| Czauż-Andrzejuk, A | 1 |
| Citko, J | 1 |
| Dybowska, D | 1 |
| Halota, W | 1 |
| Pawłowska, M | 1 |
| Laurans, Ł | 1 |
| Deroń, Z | 1 |
| Buczyńska, I | 1 |
| Simon, K | 2 |
| Białkowska, J | 1 |
| Tronina, O | 2 |
| Flisiak, R | 2 |
| Poordad, F | 1 |
| Castro, RE | 1 |
| Asatryan, A | 1 |
| Aguilar, H | 1 |
| Cacoub, P | 1 |
| Dieterich, D | 1 |
| Marinho, RT | 1 |
| Carvalho, A | 1 |
| Siddique, A | 1 |
| Hu, YB | 3 |
| Charafeddine, M | 1 |
| Bondin, M | 1 |
| Khan, N | 1 |
| Felizarta, F | 1 |
| Shafie, AA | 1 |
| Abu Hassan, MR | 1 |
| Ong, SC | 1 |
| Virabhak, S | 1 |
| Gonzalez, YS | 2 |
| Deutsch, L | 1 |
| Houri, I | 1 |
| Ben-Ari, Z | 1 |
| Shlomai, A | 1 |
| Veitsman, E | 1 |
| Cohen-Ezra, O | 1 |
| Issachar, A | 1 |
| Mor, O | 1 |
| Gozlan, Y | 1 |
| Bruck, R | 1 |
| Menachem, Y | 1 |
| Zelber-Sagi, S | 1 |
| Katchman, H | 1 |
| Shibolet, O | 1 |
| Ngwaga, T | 1 |
| Kong, L | 1 |
| Lin, D | 1 |
| Schoborg, C | 1 |
| Taylor, LE | 1 |
| Mayer, KH | 1 |
| Klein, RS | 1 |
| Celentano, DD | 1 |
| Sobel, JD | 1 |
| Jamieson, DJ | 1 |
| King, CC | 1 |
| Tavis, JE | 1 |
| Blackard, JT | 1 |
| Wyles, D | 1 |
| Saag, M | 1 |
| Viani, RM | 1 |
| Lalezari, J | 1 |
| Adeyemi, O | 1 |
| Bhatti, L | 1 |
| Khatri, A | 4 |
| King, JR | 2 |
| Trinh, R | 2 |
| Shulman, NS | 2 |
| Ruane, P | 1 |
| Rockstroh, JK | 1 |
| Feld, JJ | 2 |
| Chevaliez, S | 1 |
| Cheng, K | 1 |
| Wedemeyer, H | 1 |
| Sarrazin, C | 1 |
| Maasoumy, B | 1 |
| Herman, C | 1 |
| Hackett, J | 1 |
| Dawson, GJ | 1 |
| Cloherty, G | 1 |
| Pawlotsky, JM | 1 |
| Durlik, M | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Buivydiene, A | 1 |
| Katzarov, K | 1 |
| Kupcinskas, L | 1 |
| Tolmane, I | 1 |
| Karpińska, E | 1 |
| Pisula, A | 1 |
| Karwowska, KM | 1 |
| Bolewska, B | 1 |
| Jabłkowski, M | 1 |
| Rostkowska, K | 2 |
| Jakutiene, J | 1 |
| Simonova, M | 1 |
| Lubel, J | 1 |
| Strasser, S | 1 |
| Stuart, KA | 1 |
| Dore, G | 1 |
| Thompson, A | 1 |
| Pianko, S | 1 |
| Bollipo, S | 1 |
| Mitchell, JL | 1 |
| Fragomeli, V | 1 |
| Jones, T | 1 |
| Chivers, S | 1 |
| Gow, P | 1 |
| Iser, D | 1 |
| Levy, M | 1 |
| Tse, E | 1 |
| Gazzola, A | 1 |
| Cheng, W | 1 |
| Nazareth, S | 1 |
| Galhenage, S | 1 |
| Wade, A | 1 |
| Weltman, M | 1 |
| Wigg, A | 1 |
| MacQuillan, G | 1 |
| Sasadeusz, J | 1 |
| George, J | 1 |
| Zekry, A | 1 |
| Roberts, SK | 1 |
| El Kassas, M | 1 |
| Elbaz, T | 1 |
| Hafez, E | 1 |
| Wifi, MN | 1 |
| Esmat, G | 1 |
| Lemaitre, F | 1 |
| Ben Ali, Z | 1 |
| Tron, C | 1 |
| Jezequel, C | 1 |
| Boglione-Kerrien, C | 1 |
| Verdier, MC | 1 |
| Guyader, D | 1 |
| Bellissant, E | 1 |
| Szymanek-Pasternak, A | 1 |
| Gheorghe, L | 1 |
| Iacob, S | 1 |
| Curescu, M | 1 |
| Brisc, C | 1 |
| Cijevschi, C | 1 |
| Caruntu, F | 1 |
| Stanciu, C | 1 |
| Simionov, I | 1 |
| Sporea, I | 1 |
| Gheorghe, C | 1 |
| Iacob, R | 1 |
| Arama, V | 1 |
| Sirli, R | 1 |
| Trifan, A | 1 |
| Calvanese, C | 1 |
| Lisotti, A | 1 |
| Fiorenza, S | 1 |
| Mandreoli, M | 1 |
| Caletti, G | 1 |
| Fusaroli, P | 1 |
| Weil, C | 1 |
| Mehta, D | 2 |
| Koren, G | 1 |
| Pinsky, B | 2 |
| Samp, JC | 1 |
| Chodick, G | 1 |
| Shalev, V | 1 |
| Ordeig, L | 1 |
| Garcia-Cehic, D | 1 |
| Gregori, J | 1 |
| Soria, ME | 1 |
| Nieto-Aponte, L | 1 |
| Perales, C | 1 |
| Llorens, M | 1 |
| Chen, Q | 1 |
| Riveiro-Barciela, M | 1 |
| Buti, M | 1 |
| Esteban, R | 1 |
| Esteban, JI | 1 |
| Rodriguez-Frias, F | 1 |
| Quer, J | 1 |
| Saab, S | 2 |
| Hudgens, S | 1 |
| Grunow, N | 1 |
| Bao, Y | 1 |
| Navarro-Triviño, FJ | 1 |
| Muñoz-Medina, L | 1 |
| Navarro-Navarro, I | 1 |
| Ruiz-Villaverde, R | 1 |
| Bernstein, DE | 2 |
| Younes, Z | 1 |
| Vlierberghe, HV | 1 |
| Larsen, L | 1 |
| Tatsch, F | 1 |
| Ferenci, P | 2 |
| Pineda, JA | 1 |
| Rivero-Juárez, A | 1 |
| de Los Santos, I | 1 |
| Collado, A | 1 |
| Merino, D | 1 |
| Morano-Amado, LE | 1 |
| Ríos, MJ | 1 |
| Pérez-Pérez, M | 1 |
| Téllez, F | 1 |
| Palacios, R | 1 |
| Pérez, AB | 1 |
| Mancebo, M | 1 |
| Rivero, A | 1 |
| Macías, J | 1 |
| Rosene, AC | 1 |
| Gaspar, JL | 1 |
| Taramasso, L | 1 |
| Di Biagio, A | 1 |
| Bovis, F | 1 |
| Nicolini, LA | 1 |
| Antinori, A | 1 |
| Milazzo, L | 4 |
| Sollima, S | 3 |
| Gubertini, G | 1 |
| Niero, F | 1 |
| Saracino, A | 1 |
| Bruno, R | 1 |
| Borghi, V | 1 |
| Montagnani, F | 1 |
| Cattelan, A | 1 |
| Hasson, H | 1 |
| Taliani, G | 1 |
| D'Arminio Monforte, A | 1 |
| Mastroianni, C | 1 |
| Di Perri, G | 1 |
| Bigoni, S | 1 |
| Puoti, M | 1 |
| Spinetti, A | 1 |
| Gori, A | 1 |
| Boffa, N | 1 |
| Cacopardo, B | 1 |
| Giacometti, A | 1 |
| Parruti, G | 1 |
| Vullo, V | 1 |
| Chirianni, A | 1 |
| Teti, E | 1 |
| Pasquazzi, C | 1 |
| Segala, D | 1 |
| Andreoni, M | 1 |
| Martinello, M | 1 |
| Bhagani, S | 1 |
| Gane, E | 1 |
| Orkin, C | 1 |
| Cooke, G | 1 |
| Dore, GJ | 1 |
| Petoumenos, K | 1 |
| Applegate, TL | 1 |
| Tu, E | 1 |
| Marks, P | 1 |
| Pagani, N | 1 |
| Grebely, J | 1 |
| Nelson, M | 1 |
| Matthews, GV | 1 |
| Wong, YJ | 1 |
| Chew, SY | 1 |
| Hsiang, JC | 2 |
| Thurairajah, PH | 2 |
| Kumar, R | 2 |
| Teo, EK | 1 |
| Gokhale, RS | 1 |
| Noor, IBM | 1 |
| Tan, J | 2 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Laguno, M | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Mallolas, J | 1 |
| Londoño, MC | 1 |
| Lee, TY | 1 |
| Yang, SS | 1 |
| Fushiya, N | 1 |
| Takagi, I | 1 |
| Nishino, H | 1 |
| Akizuki, S | 1 |
| Ohnishi, A | 1 |
| Andreone, P | 2 |
| Colombo, MG | 1 |
| Enejosa, JV | 1 |
| Koksal, I | 1 |
| Maieron, A | 1 |
| Müllhaupt, B | 1 |
| Horsmans, Y | 1 |
| Weiland, O | 1 |
| Reesink, HW | 1 |
| Rodrigues, L | 1 |
| Podsadecki, T | 4 |
| Bernstein, B | 2 |
| Gentile, I | 1 |
| Buonomo, AR | 1 |
| Zappulo, E | 1 |
| Borgia, G | 1 |
| Trivella, JP | 1 |
| Gutierrez, J | 1 |
| Martin, P | 1 |
| Badri, P | 1 |
| Dutta, S | 4 |
| Coakley, E | 1 |
| Cohen, D | 1 |
| Ding, B | 2 |
| Awni, W | 2 |
| Menon, R | 2 |
| Gamal, N | 1 |
| Torre, A | 1 |
| Calvi, E | 1 |
| Regalia, E | 1 |
| Antinori, S | 1 |
| Huber, C | 1 |
| Wang, A | 1 |
| Juday, T | 1 |
| Wang, H | 1 |
| Cattaneo, D | 2 |
| Riva, A | 1 |
| Clementi, E | 1 |
| Gervasoni, C | 2 |
| Krastev, Z | 1 |
| Jelev, D | 1 |
| Antonov, K | 1 |
| Petkova, T | 1 |
| Atanasova, E | 1 |
| Zheleva, N | 1 |
| Tomov, B | 1 |
| Boyanova, Y | 1 |
| Mateva, L | 1 |
| Pockros, PJ | 1 |
| Reddy, KR | 1 |
| Mantry, PS | 1 |
| Cohen, E | 1 |
| Bennett, M | 1 |
| Sulkowski, MS | 1 |
| Wang, D | 1 |
| Abunimeh, M | 1 |
| Lawitz, E | 1 |
| D'Avolio, A | 1 |
| Micheli, V | 1 |
| Lam, JT | 1 |
| Salazar, L | 1 |
| Silverman, E | 1 |
| Ioannou, GN | 1 |
| Beste, LA | 1 |
| Chang, MF | 1 |
| Green, PK | 1 |
| Lowy, E | 1 |
| Tsui, JI | 1 |
| Su, F | 1 |
| Berry, K | 1 |
| Badri, PS | 1 |
| Parikh, A | 1 |
| Coakley, EP | 1 |
| Awni, WM | 2 |
| Menon, RM | 3 |
| Chidi, AP | 1 |
| Bryce, CL | 1 |
| Donohue, JM | 1 |
| Fine, MJ | 1 |
| Landsittel, DP | 1 |
| Myaskovsky, L | 1 |
| Rogal, SS | 1 |
| Switzer, GE | 1 |
| Tsung, A | 1 |
| Smith, KJ | 1 |
| Magri, A | 1 |
| Ozerov, AA | 1 |
| Tunitskaya, VL | 1 |
| Valuev-Elliston, VT | 1 |
| Wahid, A | 1 |
| Pirisi, M | 1 |
| Simmonds, P | 1 |
| Ivanov, AV | 1 |
| Novikov, MS | 1 |
| Patel, AH | 1 |
| Marshall, G | 1 |
| Mensing, S | 1 |
| Eckert, D | 1 |
| Sharma, S | 1 |
| Polepally, AR | 1 |
| Podsadecki, TJ | 1 |
| Yesmembetov, K | 1 |
| Ashimkhanova, A | 1 |
| Kaliaskarova, K | 1 |
| Abad, S | 1 |
| Vega, A | 1 |
| Hernández, E | 1 |
| Mérida, E | 1 |
| de Sequera, P | 1 |
| Albalate, M | 1 |
| Macías, N | 1 |
| Milla, M | 1 |
| López-Gómez, JM | 1 |
| Ishikawa, T | 1 |
| Ichida, T | 1 |
| Ishimoto, Y | 1 |
| Yokoyama, J | 1 |
| Nomoto, M | 1 |
| Ebe, Y | 1 |
| Usuda, H | 1 |
| Naito, M | 1 |
| Asakura, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure[NCT02646111] | Phase 3 | 120 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic[NCT01674725] | Phase 3 | 187 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus [NCT01716585] | Phase 3 | 636 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C V[NCT01715415] | Phase 3 | 395 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis [NCT01767116] | Phase 3 | 419 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis [NCT01833533] | Phase 3 | 305 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal[NCT02207088] | Phase 3 | 68 participants (Actual) | Interventional | 2014-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01674725)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 42.0 |
| ABT-450/r/ABT-267 and ABT-333 | 5.5 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333 with and without RBV) compared with the historical control rate for noncirrhotic, treatment-experienced participants with HCV GT1b infection treated with telaprevir and peginterferon (pegIFN)/RBV." (NCT01674725)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.7 |
| ABT-450/r/ABT-267 and ABT-333 | 100 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333 with and without RBV) compared with the historical control rate for noncirrhotic, treatment-experienced participants with HCV GT1b treated with telaprevir and pegIFN/RBV; and the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333 compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01674725)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.7 |
| ABT-450/r/ABT-267 and ABT-333 | 100 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
| ABT-450/r/ABT-267 and ABT-333 | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01674725)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to Suppress | |
| ABT-450/r/ABT-267 and ABT-333 | 0 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 95.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 98.0 |
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline. (NCT01716585)
Timeframe: At 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| Placebo | 15.8 |
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid [HCV RNA] ≥ lower limit of quantification [LLOQ] after HCV RNA < LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0.2 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.4 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01716585)
Timeframe: Within 12 weeks post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.5 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.7 |
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline. (NCT01715415)
Timeframe: At 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.9 |
| Placebo | 12.8 |
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid [HCV RNA] ≥ lower limit of quantification [LLOQ] after HCV RNA < LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.3 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01715415)
Timeframe: Within 12 weeks post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 2.4 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01767116)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 51.2 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.4 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b infection treated with telaprevir and peginterferon/RBV (pegIFN)." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100.0 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary endpoint was the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b treated with telaprevir and pegIFN/RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of particpants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01767116)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0.5 | 0 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01833533)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 42.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.9 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and peginterferon(pegIFN)/RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and pegIFN/RBV; and the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 5.2 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01833533)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 2.9 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after < LLOQ during treatment, confirmed increase of > 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment. (NCT02207088)
Timeframe: Up to 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA < LLOQ at the end of treatment. (NCT02207088)
Timeframe: Within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 1.5 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 94.1 |
9 reviews available for uracil and Hepatitis C
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.
Topics: 2-Naphthylamine; Animals; Antiviral Agents; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Hep | 2017 |
Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed.
Topics: 2-Naphthylamine; Adrenal Cortex Hormones; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2018 |
VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature.
Topics: Adult; Drug Combinations; Hepatitis C; Humans; Lung Diseases, Interstitial; Macrocyclic Compounds; M | 2019 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Top | 2014 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; | 2015 |
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dr | 2015 |
New combination antiviral for the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; H | 2016 |
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Inte | 2017 |
15 trials available for uracil and Hepatitis C
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Coinfection; | 2020 |
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, | 2020 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2020 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbama | 2017 |
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, C | 2017 |
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2018 |
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Admin | 2018 |
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Dru | 2014 |
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Cyclop | 2015 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropan | 2016 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relation | 2016 |
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyc | 2016 |
38 other studies available for uracil and Hepatitis C
| Article | Year |
|---|---|
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interacti | 2022 |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, | 2022 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combina | 2019 |
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; | 2020 |
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genot | 2020 |
Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Antiviral Agents | 2020 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopr | 2017 |
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Topics: 2-Naphthylamine; Aged; Anilides; Antibiotics, Antineoplastic; Antiviral Agents; Carbamates; Cyclopro | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; D | 2017 |
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Sustained virological response after 4-week ritonavir-boosted paritaprevir, ombitasvir and dasabuvir plus ribavirin treatment in a kidney transplant recipient.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Hepatitis C; Humans; Kidney Transpla | 2017 |
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equ | 2018 |
Inductive Effect of a Ritonavir-Containing Hepatitis C Treatment Regimen on Warfarin in a Patient-A Case Report.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitor | 2019 |
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.
Topics: 2-Naphthylamine; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filt | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepat | 2018 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Cre | 2019 |
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dr | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhib | 2015 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, C | 2016 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug | 2016 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropa | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropa | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infec | 2016 |
Payers Sued Over Coverage Of Expensive Hepatitis C Drugs.
Topics: Drug Combinations; Drug Costs; Hepatitis C; Insurance, Health; Macrocyclic Compounds; Ritonavir; Sof | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cycl | 2016 |
Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication.
Topics: Acetanilides; Antiviral Agents; Cell Line, Tumor; Cell Survival; DNA Replication; Drug Resistance, V | 2016 |
Falling up stairs.
Topics: 2-Naphthylamine; Accidental Falls; Anilides; Antiviral Agents; Bronchodilator Agents; Carbamates; Cu | 2016 |
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, P | 2017 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2016 |
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |